It was a triumph of medical science over tragedy.
The case involved a 29-year-old woman suffering an ectopic pregnancy in which the embryo becomes embedded outside the uterus, usually in one of the fallopian tubes.
Often, in such instances, in order to save the life of the mother, termination of the pregnancy is the only remedy.
But Malcolm Pearce, an obstetrician at St Georges Hospital Medical School, London, had performed a minor miracle.
He had successfully extracted the embryo, then reimplanted it into the patients womb.
And she had gone on to have a healthy baby. It was a feat numerous other surgeons had tried but failed to achieve.
The astonishing story was reported in the British Journal Of Obstetrics and made headlines around the world.
No doubt it also offered hope to the thousands of women who suffer such traumatic events each year.
Malcolm Pearce (pictured) was sacked, found guilty of serious professional misconduct and struck off the medical register for falsifying a medical study
Or rather, it would have if it hadnt turned out to have been a lie.
Shortly after publication, in 1995, the journal was approached by a whistleblower at St Georges claiming that Pearces story was a fabrication.
Investigations subsequently revealed the surgeon had tampered with computer records and amalgamated patients notes those of a woman who was dead and another who had miscarried to create a fictitious patient.
Pearce, who it transpired had falsified another study into drugs to prevent miscarriage, was sacked, found guilty of serious professional misconduct and struck off the medical register.
We speak to experts exposing the scandal of fake medical research
It is a disturbing tale. But not a one-off. According to bombshell allegations from a group of highly respected experts, the medical world is rife with research fraud.
Their investigations suggest up to one in five of the estimated two million medical studies published each year could contain invented or plagiarised results, details of patients who never existed and trials that didnt actually take place.
The problem is well known about in science circles, says Richard Smith, former editor-in-chief of the British Medical Journal (BMJ) yet there is a reluctance within the establishment to accept the scale of the problem.
In a recent article, he suggested the only way to combat research fraud is for journal editors to view all studies submitted as potential fakes until they can be proven otherwise.
Speaking on The Mail on Sundays Medical Minefield podcast, Smith who was involved in the investigations that exposed Malcolm Pearce said: Its shocking, but common.
Many of these fraudulent studies are simply invented. There were no patients. The trial never happened.
Research coming out of countries where doctors are commonly rewarded with pay rises for publishing their work such as Egypt, Iran, India and China is more likely to be faked, investigations show.
In China, doctors can only get promoted if they score enough points, by getting published, says John Carlisle, an NHS anaesthetist who spends his spare time hunting for fraudulent medical studies.
Korean pioneer Woo Suk Hwang (pictured) became a national hero when he and his research team reportedly cloned a human embryo and extracted stem cells from it a technique that could potentially cure a wide range of diseases. The claims turned out to be bogus.
Meanwhile, Professor Lisa Bero, an expert in study fraud at Cochrane, one of the worlds foremost research organisations, warns of paper mills shadowy companies that operate online, churning out sham studies much like the essay mills that profit by selling work to students.
Academics investigating these paper mills recently flagged more than 1,000 potential research fraud cases linked to them.
Paper mills can generate hundreds of fraudulent studies, far more than the odd bad egg researcher, and saturate certain topics, such as cardiology. I expect well only see more of it in the future, adds Prof Bero.
Despite being vocal about their concerns, Smith and others argue little has been done within the mainstream medical world over the past few decades to stem the tide of tainted data, which means it will likely have been used to underpin NHS medical guidance, potentially putting lives at risk.
I have no doubt that this is a major threat to global public health, warns Ian Roberts, Professor of Epidemiology at the London School of Hygiene & Tropical Medicine, who claims the regulatory systems are not fit for purpose.
In the mid-1990s, South African oncologist Dr Werner Bezwoda claimed to have effectively cured women with late-stage breast cancer by giving them bone-marrow transplants.
His findings, published in major medical journals, were later revealed to have been invented but not before thousands of patients had died after undergoing the ineffective treatment.
Eric Poehlman, a Canadian researcher, was the first and one of the only scientists to be jailed for research fraud after ten of his publicly funded studies looking at weight gain in the menopause, ageing and hormone-replacement therapy were found to be fabricated.
Then theres Korean pioneer Woo Suk Hwang, who became a national hero when he and his research team reportedly cloned a human embryo and extracted stem cells from it a technique that could potentially cure a wide range of diseases. The claims turned out to be bogus.
The Covid pandemic, and the global rush to find treatments, has been rife with research fraud, says Prof Bero.
An investigation found that more than a third of the 26 studies into anti-parasitic medication ivermectin, which many hoped could ease Covid symptoms, have signs of potential fraud.
Studies last year looking at whether the antimalarial hydroxychloroquine could reduce Covid severity it was touted as a wonder drug by President Trump were also revealed to have grave flaws.
In 2010, Prof Roberts was involved in a review that flagged up false data in 90 published studies on drugs given to regulate blood pressure during surgery, all authored by the same German anaesthesiologist, Joachim Boldt (pictured)
One, which led to French health chiefs recommending the medication, was found to contain disputed data.
The expert behind it, Marseilles-based microbiologist Didier Raoult, initially threatened legal action against one of the scientists who flagged up anomalies in dozens of his studies.
But Raoult is now due to appear before an ethics committee, accused of spreading false information about the benefits of the medication.
Raoults lawyer has reportedly said his client would be cleared.
Two other major studies that concluded the drug didnt have an effect on Covid were also exposed as potential fakes.
These concluded that hydroxychloroquine was linked to increased deaths and heart problems and were published in world-renowned journals The Lancet and The New England Journal Of Medicine.
They led to the World Health Organisation and several countries halting trials into the drug.
But within days, glaring errors were discovered. Eagle-eyed readers noticed that death rates failed to match official records, and hospitals mentioned in the study later denied ever having provided patient data.
Surgisphere, the company which provided the figures, headed up by US vascular surgeon Dr Sapan Desai, failed to produce detailed patient records when requested.
The papers were retracted. The New England Journal Of Medicine published a statement by the studys authors in which they claimed they were unable to validate the data sources underlying the article, as they were not granted access to the raw data and apologised for difficulties caused.
Commentators have questioned how the respected doctors and editors who reviewed the study before publication failed to spot the problems.
However The Lancets editor Richard Horton called the paper retracted by his journal a fabrication and a monumental fraud.
Anaesthetists became suspicious about studies carried out by Japanese researcher Yoshitaka Fujii (pictured) into a drug given to ease nausea and vomiting after surgery.Further investigation concluded that more than 100 trials he had claimed to have carried out were totally fabricated
He added: If you have an author who deliberately tries to mislead, its surprisingly easy for them to do so.
While these are eye-opening examples, far more common, says Carlisle, are low-level fakes studies that simply confirm what other studies say, so arouse little suspicion.
He adds: Youd think people would manufacture startling results, but in my experience most studies are fairly boring just interesting enough to get published, so they can go on the CV.
For a drug to be licensed for use, manufacturers are legally required to carry out clinical trials to prove it is safe and works.
Once approved, doctors and other researchers are then able to easily use the medicine on patients in their own trials, in order to show how best to use it.
This means there can be hundreds, or even thousands of studies published on certain treatments, all producing differing results and this creates the perfect camouflage for fabricated studies.
In order to produce a more definitive picture, rather than rely on the results of one or two trials, experts carry out systematic reviews, rounding up and assessing numerous studies and looking at the totality of evidence.
If there was the odd fake study, by simple law of averages, a review might effectively neutralise the impact. However, given the sheer scale of the problem of research fraud, fake studies may actually skew the results of reviews, too.
Prof Ian Roberts first became aware of research fraud in the late 1990s while he was carrying out one such systematic review on trials of a drug called mannitol, which was given to reduce brain swelling after head injury.
In the mid-1990s, South African oncologist Dr Werner Bezwoda (pictured) claimed to have effectively cured women with late-stage breast cancer by giving them bone-marrow transplants his findings had been invented
He had concluded the treatment was effective when a colleague suggested that some of the trials had been fabricated.
Prof Roberts says: Three of the mannitol papers had come from Brazil, which was where this guy was from.
He said it was well known, in the medical world there, that many of these trials hadnt actually taken place.
He began to investigate, and discovered, to his horror, that his colleague was right. When he contacted the authors and institutes named on the papers, they either claimed to have no knowledge of the trial mentioned or couldnt provide any further evidence that they took place.
Theyd been fabricated. I could find no other explanation, he says.
When Prof Roberts then removed these problematic studies from his review of Mannitol, the conclusion changed it was not an effective treatment for head injuries.
He says: These fraudulent studies could have meant patients were not given the best treatment, and lives were put at risk.
I flagged it up to the research group I was working for, put it down to bad luck and carried on.
But then it happened again. In 2010, Prof Roberts was involved in a review that flagged up false data in 90 published studies on drugs given to regulate blood pressure during surgery, all authored by the same German anaesthesiologist, Joachim Boldt.
These trials had been published over many years in leading journals, but it turned out they had never happened, says Prof Roberts.
Again, when they were excluded from the review, it showed the treatment was not effective. British surgical guidelines had to be changed.
It made me realise, if someone can get away with fabricating 90 studies, the system isnt working.
Before a study is published in a medical journal, it goes through a process of peer review.
This means other researchers who are not known to the author scrutinise it to look for potential errors.
Surgisphere, a company which provided figures for a potential Covid drug study, headed up by US vascular surgeon Dr Sapan Desai (pictured), failed to produce detailed patient records when requested
However, it is a system entirely based on trust, that the study actually took place, explains former BMJ editor Richard Smith.
For this reason he calls it a flawed process, adding If the author of a paper says there was 200 patients, we assume there were 200.
We dont say, show us their signatures. Just because something had passed through peer review, doesnt mean it isnt fraudulent.
Its difficult to know for certain how widespread the problem of research fakery is.
Roughly four in every 10,000 published end up being retracted withdrawn by the journal in question according to an analysis by Science magazine.
This can be due to honest errors, but in two-thirds of cases there is a suspicion of fraud. The work of NHS anaesthetist John Carlisle may point to further answers.
He first became aware of bogus studies 20 years ago, after he and other anaesthetists became suspicious about studies carried out by Japanese researcher Yoshitaka Fujii into a drug given to ease nausea and vomiting after surgery.
The side-effect rates between the trails were strikingly similar, and identical in some cases, he says. Youd expect some variation.
Further investigation concluded that more than 100 trials he had claimed to have carried out were totally fabricated.
Fujii lost his university job, and by 2010 no fewer than 183 of his papers had been retracted, or withdrawn by the journals that published them.
Despite this, Fujii maintains he did nothing wrong.
Carlisle refined his methods and has carried out two major investigations into research fraud.
By looking for too-good-to-be-true patterns in the data, he found that one study in five published by one journal, Anaesthesia, was potentially fraudulent.
Authors from five countries submitted the majority of trials 48 per cent of Chinese trials, 62 per cent of Indian trials and 90 per cent of Egyptian trials were suspected fakes. A third of South Korean and a fifth of Japanese trials were also possibly bogus.
A similar analysis of more than 5,000 studies published in major journals, including The New England Journal Of Medicine and the Journal Of The American Medical Association, confirmed his early finding, suggesting that 15 per cent could be fraudulent.
Anaesthesia, and the New England Journal, now use Carliles methods to screen all studies submitted for publication, in order to weed out any fakes.
It all begs the questions: why would scientists lie particularly when there are such severe consequences, both in terms of damaging public health, and, should they be caught, on their own careers?
Eric Poehlman (pictured), a Canadian researcher, was the first and one of the only scientists to be jailed for research fraud after ten of his publicly funded studies looking at weight gain in the menopause, ageing and hormone-replacement therapy were found to be fabricated
People lie because its easier than doing a study for real, suggests Carlisle.
Richard Smith agrees: You cant get on in the academic world if you dont publish, and doing studies properly can be a long and difficult process.
You need funding, skills, and a team. In some ways, its easier to simply invent it. And the terrible thing is that its quite easy to get away with it.
Prof Ian Roberts claims he has warned British health watchdog the National Institute for Health and Care Excellence (NICE), the Chief Medical Officers and others about the scale of the problem, but has been all but ignored.
He says: We have written to them but they are not interested. I can understand why no one wants to take it seriously this is a difficult problem to solve and will require huge changes in the way things are done.
When The Mail on Sunday contacted the office of the Chief Medical Officers, it claimed to have no record of Prof Robertss letters despite the fact that we have seen the letter of acknowledgment from Englands Chief Medical Officer, Professor Chris Whitty.
A Government spokesperson said: Clinical Trials are required by law to be conducted to Good Clinical Practice.
This is a set of internationally recognised ethical and scientific quality requirements that must be followed when designing, conducting, recording and reporting clinical trials that involve people.
Read more from the original source:
- Here's Why Longeveron Is Surging Today - Motley Fool - December 4th, 2021
- Global Regenerative Medicine Partnering Report/Directory 2021: Terms and Agreements for 1600 Deals 2014-2 - Benzinga - December 4th, 2021
- CAR T-Cell Therapy Market is anticipated to reach US$ 2.8 Bn by 2031 - PRNewswire - December 4th, 2021
- Stem-cell implant prototypes pave the way towards life-long treatment for type 1 diabetes - ZME Science - December 3rd, 2021
- Certain Patients With Heart Failure May Benefit From Stem Cell Therapy - Pharmacy Times - December 3rd, 2021
- Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update - Yahoo Finance - December 3rd, 2021
- Roundtable Discussion: Usmani and Participants Review Using Transplant and Combination Therapy in a Patient With Newly Diagnosed Multiple Myeloma -... - December 3rd, 2021
- Hematopoiesis and innate immunity: an inseparable couple for good and bad times, bound together by an hormetic relationship - DocWire News - December 3rd, 2021
- Reality of universal cancer prevention & cure - BSA bureau - December 3rd, 2021
- World Aids Day Improving the lives of everyone affected by HIV - QMUL - December 3rd, 2021
- Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an Investigational Microbiome Therapeutic to Reduce the Risk of... - December 3rd, 2021
- AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and... - November 28th, 2021
- The questions surgical robots still need to answer - Becker's Orthopedic & Spine - November 24th, 2021
- Holiday Gift Guide 2021: The Best Wellness And Self-Care Essentials For Travel - Forbes - November 24th, 2021
- Investigating pathogens and their life cycles, for the benefit of society - MIT News - November 24th, 2021
- Mitigating Toxicities Will Position BCMA for Role in Triple-Class Refractory Multiple Myeloma - OncLive - November 24th, 2021
- Human Primary Cells Market 2021 | Know the Latest COVID19 Impact Analysis and Strategies of Key Players: Lonza, Thermo Fisher Scientific,... - November 21st, 2021
- Researcher Works for Diversity, Inclusion in Sciences, One Journal at a Time - Lab Manager Magazine - November 18th, 2021
- Raw Marijuana Won't Get You Stoned, But It Does Have Some Interesting Benefits - Benzinga - Benzinga - November 16th, 2021
- The 18 Best New November 2021 Skin-Care Launches That Deserve a Spot in Your Routine - Allure - November 16th, 2021
- Singapore Aims To Lead The World In Lab-Grown Meat - Intelligent Living - November 16th, 2021
- Dermarolling Your Scalp Is Proven to Increase Hair Growth and Thickness Here's How to Do It - Yahoo Lifestyle - November 15th, 2021
- Stem Cell Therapy for Heart Failure Reduces CV Events, Death in Select Patientsbut not Hospitalization - AJMC.com Managed Markets Network - November 15th, 2021
- JASPER THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.com - November 15th, 2021
- Week In Review: Zai Lab Announces Two In-Licensings With Total Value Of $800 Million - Seeking Alpha - November 15th, 2021
- Beam gets green light to begin first clinical test of base editing - BioPharma Dive - November 15th, 2021
- GlycoMimetics GMI-1359 Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting and Exposition - Galveston County... - November 15th, 2021
- Jasper Therapeutics to Present at the Credit Suisse 30th Annual Virtual Healthcare Conference - GlobeNewswire - November 11th, 2021
- Biotech Companies are Expanding the Frontiers of Engineered Cell Therapy - BioSpace - November 11th, 2021
- Fate Therapeutics Announces Abstract Highlighting FT538 and - GlobeNewswire - November 11th, 2021
- Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer... - November 11th, 2021
- Affimed Reports Third Quarter 2021 Financial Results and Highlights Operational Progress - KULR-TV - November 11th, 2021
- Jasper Therapeutics to Present at the Credit Suisse 30th Annual Virtual Healthcare Conference - Yahoo Finance - November 9th, 2021
- CELLECTAR BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.com - November 9th, 2021
- Hoth Therapeutics Inks API and Drug Product Contracts with WuXi STA to Advance Manufacturing of HT-KIT Cancer Therapeutic - PRNewswire - November 9th, 2021
- Technology set to redesign the future of food as agriculture moves towards net zero - ABC News - November 9th, 2021
- MAGENTA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - marketscreener.com - November 5th, 2021
- Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology... - November 5th, 2021
- 15 Best Peptide Skin-Care Products 2021 for Smoother, Firmer, and Plumper Skin - Allure - November 5th, 2021
- Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of... - November 5th, 2021
- CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results - GlobeNewswire - November 5th, 2021
- Fate Therapeutics Announces Eight Presentations at the 2021 ASH Annual Meeting - The Bakersfield Californian - November 5th, 2021
- STEMTECH CORPORATION (OTC:GNTW) ANNOUNCES APPOINTMENT OF SANDRA KAZICKAITE TO THE ROLE OF VICE PRESIDENT OF GLOBAL PERFORMANCE - Yahoo Finance - November 3rd, 2021
- Assessing the benefits of stem cell research (column) - LNP | LancasterOnline - November 1st, 2021
- How to Test for Leukemia: What Are My Options? - Healthline - November 1st, 2021
- To Reduce Stress and Boost Energy, Try Maca Root - The Beet - November 1st, 2021
- In Vitro Toxicology Testing Market Outlook 2021 Pricing Strategy, Industry Latest News, Top Company Analysis, Research Report Analysis and Share by... - November 1st, 2021
- Geron Enters New Innovative Licensing and Access Pathway in the United Kingdom for Imetelstat - Business Wire - November 1st, 2021
- Stem Cell Diseases: What Can Stem Cells Cure | stemcela.com - October 30th, 2021
- The Cost Of Stem Cell Therapy in 2021 | BioInformant - October 30th, 2021
- NIH Guidelines for Human Stem Cell Research | STEM Cell ... - October 30th, 2021
- Fi Europe 2021 innovation finalists mirror mega trends of plant based and sustainability - FoodNavigator.com - October 30th, 2021
- Types of Oncology Drugs - Healthline - October 28th, 2021
- Medical Innovation In Pet Healthcare Is Taking Things Up a Notch - Entrepreneur - October 28th, 2021
- BIOHAVEN ENROLLS PHASE 1A/1B CLINICAL TRIAL OF BHV-1100, LEAD ASSET FROM ITS ARM (ANTIBODY RECRUITING MOLECULE) PLATFORM, IN COMBINATION WITH NK CELL... - October 28th, 2021
- Researchers discover a way to increase the effectiveness of antibiotics - EurekAlert - October 28th, 2021
- Fresh Bros: Exploring the Top Five Health Benefits of Turmeric Extract with BioPerine - GlobeNewswire - October 28th, 2021
- All hopes to save the northern white rhinos now rest on a single female - ZME Science - October 23rd, 2021
- AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1 - StreetInsider.com - October 21st, 2021
- CDMO: The Rise of End-to-End Services - Marketscreener.com - October 21st, 2021
- MeiraGTx Announces the Presentation of Two Novel Inherited - GlobeNewswire - October 21st, 2021
- Current status of drug repositioning in hematology - DocWire News - October 19th, 2021
- Is Fresh Breast Milk Better for Preemies Than Pumped and Stored? - UMass News and Media Relations - October 19th, 2021
- Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem... - October 19th, 2021
- Headband Could Beat Insomnia By Zapping The Brain While Sufferers Wear It For 20 Minutes At Bedtime - - Todayuknews - October 19th, 2021
- BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization -... - October 17th, 2021
- Misinformation on stem cell treatments for COVID-19 linked to overhyped science, researchers argue - EurekAlert - October 17th, 2021
- FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer - BioSpace - October 17th, 2021
- Nic Chapman: my MS battle and the treatment that's given me hope - The Times - October 17th, 2021
- Dream Body Clinic Stem Cell Therapy Stem Cells HGH - October 13th, 2021
- Hematopoietic Stem Cells - October 13th, 2021
- 3D printing: Healthcare insiders' view on the tech - Verdict - October 13th, 2021
- Top 10 Best Stem Cell Supplement Brands - Healthtrends - October 13th, 2021
- Mitochondrial superoxide dismutase overexpression and low oxygen conditioning hormesis improve the performance of irradiated sterile males |... - October 13th, 2021
- Researchers uncover how cancer cells use sugar residue to evade the immune system - News-Medical.net - October 13th, 2021
- The science and practicality of cultured meat The Stute - The Stute - October 11th, 2021
- Vitro Biopharma Inc. July 31st 2021; 3rd Quarter ended Financial Results of Operations and Shareholder Le - Benzinga - October 11th, 2021
- Want To Support Healthy Bones? It's Time To Get Your Vitamin D In Check - mindbodygreen.com - October 11th, 2021
- Joint : Why Breast Cancer Awareness Matters, and How to Get It Done - marketscreener.com - October 11th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - KY3 - October 7th, 2021